In the Mix: 8 More Articles — February 26, 2026

Medterra CBD Review: Products, Testing Standards & Our Experience – Forbes

Medterra offers CBD products with third-party testing documentation and certificates of analysis available through their website, providing some verification of cannabinoid content and purity. However, product pages lack comprehensive ingredient transparency, requiring clinicians to access separate testing documents for full formulation details. While this tiered information structure meets emerging industry standards for quality assurance, it creates modest friction in clinical product evaluation compared to complete on-page disclosure. For practitioners considering CBD recommendations, the availability of independent testing certificates represents a reasonable baseline for quality verification in a market with inconsistent transparency practices. The separation of detailed testing results from product marketing pages may reflect liability considerations rather than quality deficiencies, though streamlined disclosure would better support evidence-based clinical decision making. This review remains clinically relevant for understanding current quality assurance practices and documentation standards that clinicians should expect when evaluating commercial CBD products.

R&R CBD Review: Products, Testing Standards & Our Experience – Forbes

R&R CBD manufactures multi-cannabinoid formulations combining CBD with additional cannabinoids in both THC-containing and THC-free products. The Forbes review examines the company’s analytical testing standards and product quality metrics, though clinical evidence specific to these formulations remains limited. Understanding third-party testing protocols and cannabinoid standardization practices across commercial suppliers is relevant for clinicians counseling patients about product selection and safety. This review may provide useful context for practitioners discussing cannabinoid product characteristics with patients already committed to this therapeutic approach. The article remains worth reading because standardization and testing transparency are foundational safety considerations when patients are already using or considering cannabis-derived products.

CBDistillery Review: Products, Testing Standards & Our Experience – Forbes

CBDistillery employs third-party laboratory testing to verify cannabinoid content and potency, providing documented cannabinoid concentrations and terpene profiles relevant for patients seeking consistent dosing. This testing approach addresses the significant clinical problem of cannabinoid product standardization and labeling accuracy that persists in unregulated markets. While third-party testing does not establish clinical efficacy or safety for specific medical conditions, it represents an important quality control measure that distinguishes some commercial products from untested alternatives. For clinicians whose patients are already using over-the-counter cannabinoid products, understanding quality differentials among available products may help contextualize patient-reported outcomes and product reliability. This article remains clinically relevant because standardized cannabinoid dosing and transparent labeling are foundational prerequisites for any future rigorous clinical research on cannabis therapeutics.

Arizona senator proposes 'public nuisance' bill for marijuana smell – YouTube

An Arizona legislator has proposed classifying excessive marijuana odor as a public nuisance, a regulatory response to increased neighbor complaints in legalized cannabis markets. The bill’s practical implementation faces significant challenges, including lack of objective odor measurement standards and questions about enforcement capacity at the local level. Clinicians may encounter patients experiencing interpersonal conflict related to cannabis use or those reporting olfactory complaints, making awareness of evolving state-level regulations contextually important for patient counseling. As legalization continues expanding, similar nuisance-based restrictions may influence cannabis consumption patterns and patient access across jurisdictions. Understanding these regulatory developments can inform discussions with patients about responsible use and community relations. The article is worth reviewing for its illustration of how public health policy continues shaping the real-world context in which patients make cannabis use decisions.

The Des – In all, 24 states have passed legislation to legalize marijuana for recreational use …

Twenty-four states have legalized recreational cannabis, with expansion continuing in regions near Iowa and beyond, reflecting a significant shift in state-level regulatory frameworks that clinicians should recognize when assessing patient cannabis use. Widening legal access is likely to increase cannabis use prevalence in both recreational and self-medication contexts, necessitating updated screening protocols and patient counseling practices in clinical settings. Providers should understand the legal status of cannabis in their region and neighboring jurisdictions to better contextualize patient use patterns and address potential health risks or drug interactions during clinical encounters. Legal availability does not eliminate cannabis-related health concerns, including respiratory effects, cognitive impacts, or interactions with medications, making evidence-based risk counseling essential regardless of legal status. Understanding state-level legalization trends helps clinicians anticipate changing patterns of cannabis exposure in their patient populations and adjust clinical practice accordingly. The article provides useful context for clinicians who need to discuss cannabis use patterns with patients and understand how changing legal

Madison Township Zoning Commission OKs site plan for marijuana facility

This article documents zoning approval for a cannabis cultivation facility in Madison Township, representing one of many local regulatory decisions expanding legal cannabis production infrastructure. While individual facility approvals have minimal direct clinical significance, the proliferation of licensed cultivation operations influences cannabis product availability, potency standardization, and supply chain characteristics within communities. Clinicians should be aware that such approvals incrementally shape the cannabis products their patients access, potentially affecting dosing consistency and contaminant profiles. As cultivation facilities become more regulated and standardized through local zoning frameworks, future clinical research access to cannabis may improve, though this remains a secondary benefit. Monitoring local cannabis facility approvals can help clinicians understand the quality and potency landscape of products their patients are obtaining. Despite its limited immediate clinical relevance, tracking such zoning decisions provides useful context for understanding community-level cannabis availability and its implications for patient counseling and harm reduction discussions.

Union County officials seize drugs, candy-branded THC products in multi-agency operation

Law enforcement in Union County conducted a multi-agency operation against unlicensed THC retailers, seizing over $100,000 in products including candy-branded items designed to appeal to children. Unregulated THC products, particularly those with pediatric-attractive packaging, pose significant public health risks due to lack of standardized dosing, quality control, and proper labeling standards. Candy-branded THC products carry particular concern for accidental pediatric ingestion and poisoning, as they are indistinguishable from legitimate confectionery to young children. Clinicians should be aware that patients, especially pediatric cases presenting with unexplained cannabis intoxication, may have encountered these illicit products in their communities. The absence of regulatory oversight means these products may contain variable THC concentrations and unknown contaminants, complicating clinical management. Clinicians may find value in reviewing this article to better understand the illicit THC product marketplace

Here's Why Tenet Healthcare (THC) is a Strong Value Stock – Yahoo Finance

This article discusses Tenet Healthcare Corporation’s financial performance and stock valuation rather than cannabis pharmacology or cannabinoid therapeutics. The content analyzes traditional investment metrics including price-to-earnings ratios and market positioning, which have no application to clinical cannabis practice or cannabinoid science. Healthcare providers and researchers seeking information on cannabinoid mechanisms, drug interactions, dosing strategies, or patient outcomes will find no actionable clinical information here. The use of the ticker symbol THC appears to be coincidental financial wordplay rather than substantive engagement with tetrahydrocannabinol or cannabis medicine. Clinicians should not allocate time to this resource for cannabis-related medical education or evidence synthesis. The article may warrant review only for those with financial interests in Tenet Healthcare or studying how misleading ticker symbol associations populate medical information feeds.